ACO2 Antibody

What is ACO2 and why is it an important research target?

ACO2 (aconitase 2, mitochondrial) is a critical enzyme in the citric acid cycle (Krebs cycle) that catalyzes the conversion of citrate to isocitrate. As a key component in cellular energy production, ACO2 plays a vital role in mitochondrial function and cellular metabolism . The protein is highly conserved across species, indicating its evolutionary importance.

ACO2 has become an important research target because dysregulation of its activity has been linked to metabolic disorders, neurodegenerative diseases (particularly Parkinson's disease), and cancer . Its central role in energy metabolism makes it a crucial marker for mitochondrial health and function. Recent studies have also revealed unexpected roles for ACO2 in immunity regulation, suggesting broader physiological importance beyond energy metabolism .

Selecting the appropriate ACO2 antibody requires careful consideration of several key factors:

• Species reactivity: Ensure the antibody has been validated for your species of interest. Current data shows antibodies with reactivity against human, mouse, rat, and pig samples .

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IHC, IF, etc.). Review the validation data, including images showing expected results .

• Clonality: Consider whether a monoclonal or polyclonal antibody better suits your needs:

  • Monoclonal antibodies (e.g., 67509-1-Ig) offer high specificity for a single epitope

  • Polyclonal antibodies (e.g., 11134-1-AP) recognize multiple epitopes and may provide stronger signals

• Immunogen information: Review the immunogen sequence to ensure it aligns with your region of interest. For example, CAB3716 was generated using a recombinant fusion protein corresponding to amino acids 501-780 of human ACO2 .

• Validation data quality: Assess the quality of supporting data, including Western blot images showing a band at the expected molecular weight (approximately 85 kDa for ACO2) .

When possible, compare antibodies from different sources and consider validating the antibody in your specific experimental system before proceeding with larger studies.

What are the optimal sample preparation protocols for ACO2 antibody applications?

Optimal sample preparation for ACO2 antibody applications varies by technique:

For Western Blot Analysis:

• Extract proteins using RIPA buffer supplemented with protease inhibitors

• Include reducing agents (e.g., DTT or β-mercaptoethanol) in sample buffer

• Heat samples at 95°C for 5 minutes to denature proteins

• Load 20-50 μg of protein per lane

• Use an 8-10% gel for optimal separation of the 85 kDa ACO2 protein

For Immunohistochemistry:

• Fix tissues with 10% neutral buffered formalin

• Perform antigen retrieval using TE buffer (pH 9.0) as primary recommendation

• Alternatively, use citrate buffer (pH 6.0) if TE buffer results are suboptimal

• Block endogenous peroxidase activity with hydrogen peroxide

• Apply primary antibody at recommended dilutions (typically 1:200-1:2000) and incubate overnight at 4°C

For Immunofluorescence:

• Fix cells with 4% paraformaldehyde for 15 minutes

• Permeabilize with 0.1-0.5% Triton X-100

• Block with 5% normal serum corresponding to the secondary antibody host

• Apply primary antibody at 1:300-1:1200 dilution

• Incubate with appropriate fluorophore-conjugated secondary antibody

• Counterstain nuclei with DAPI

Always include appropriate positive control samples that are known to express ACO2, such as brain tissue, heart tissue, or liver samples, which have been validated in multiple studies .

How can I optimize ACO2 antibody staining for co-localization studies with other mitochondrial markers?

Optimizing co-localization studies between ACO2 and other mitochondrial markers requires careful consideration of antibody compatibility and imaging parameters:

• Antibody selection considerations:

  • Choose ACO2 antibodies raised in different host species than your other mitochondrial marker antibodies to avoid cross-reactivity

  • Verify that epitopes are accessible when multiple antibodies are used simultaneously

  • Test different fixation methods, as some may preserve certain epitopes better than others

• Protocol optimization:

  • Perform sequential staining if antibodies are from the same host species

  • Use blocking peptides to prevent non-specific binding

  • Test different permeabilization conditions (0.1-0.5% Triton X-100 or 0.05-0.1% saponin)

  • Optimize antibody dilutions specifically for co-staining experiments, as these may differ from single-antibody protocols

• Imaging considerations:

  • Use confocal microscopy with appropriate filter settings to minimize spectral overlap

  • Perform sequential scanning to prevent bleed-through between channels

  • Collect Z-stacks to capture the three-dimensional structure of mitochondria

  • Apply deconvolution algorithms to improve resolution

• Quantification methods:

  • Calculate Pearson's or Mander's coefficients for objective assessment of co-localization

  • Use line scan analysis to visualize co-localization profiles

  • Consider automated image analysis tools for unbiased quantification

Common mitochondrial markers that work well for co-localization with ACO2 include Tom20 (outer membrane), COXIV (inner membrane), and mtHSP70 (matrix). Preliminary data from immunofluorescence studies using ACO2 antibodies show clear mitochondrial localization patterns in HeLa cells , making these cells a good model system for establishing co-localization protocols.

What are the common troubleshooting strategies for ACO2 antibody experiments?

When encountering issues with ACO2 antibody experiments, consider these troubleshooting strategies based on the specific problem:

For weak or no signal in Western blots:

• Increase antibody concentration or incubation time

• Enhance protein loading (50-100 μg per lane)

• Optimize transfer conditions for high molecular weight proteins (85 kDa)

• Use fresh reducing agents in loading buffer

• Try alternative blocking agents (5% BSA often works better than milk for phosphorylated proteins)

• Verify sample preparation and storage conditions haven't degraded the protein

For high background in immunostaining:

• Increase blocking time or blocking agent concentration

• Reduce primary antibody concentration

• Increase washing steps (time and number)

• Pre-adsorb antibody with tissue powder

• Optimize secondary antibody dilution

• Use specific antigen retrieval methods (TE buffer pH 9.0 is recommended for many ACO2 antibodies)

For non-specific bands in Western blot:

• Increase washing stringency

• Optimize antibody concentration

• Use more specific blocking agents

• Consider more stringent sample preparation

• Include positive and negative controls (e.g., ACO2 knockdown samples)

• Verify the antibody lot with the manufacturer

For inconsistent results between experiments:

• Standardize protein extraction and handling procedures

• Use the same lot of antibody when possible

• Include internal loading controls

• Standardize imaging and analysis parameters

• Control for environmental factors that might affect mitochondrial function

If problems persist, consider validating the antibody's specificity with ACO2 knockdown or knockout samples, as demonstrated in several publications using the 11134-1-AP antibody .

How are ACO2 antibodies used to investigate the role of ACO2 in neurodegenerative diseases?

ACO2 antibodies have become valuable tools for investigating the relationship between ACO2 dysfunction and neurodegenerative diseases, particularly Parkinson's disease (PD). Recent research has revealed significant insights:

• Biomarker development:
  Studies have shown that ACO2 activity is significantly decreased in peripheral blood mononuclear cells (PBMCs) from PD patients compared to healthy controls, while protein expression may be upregulated, suggesting a compensatory mechanism . ACO2 antibodies enable researchers to:

  • Measure ACO2 protein levels via Western blot

  • Assess its cellular localization via immunohistochemistry

  • Correlate expression patterns with disease progression

• Genetic variant investigation:
  Researchers have identified rare coding variants of ACO2 associated with increased PD vulnerability. ACO2 antibodies allow investigation of how these variants affect:

  • Protein stability and expression levels

  • Subcellular localization

  • Association with other mitochondrial proteins

• Mechanistic studies:
  ACO2 antibodies facilitate investigation of underlying disease mechanisms:

  • Monitoring mitochondrial dysfunction in cellular and animal models

  • Examining oxidative stress responses

  • Studying autophagy disruption, including decreased LC3 and Atg5 transcription via inhibited histone acetylation

• Therapeutic target validation:
  As targeting ACO2 emerges as a potential therapeutic strategy, antibodies help:

  • Validate drug target engagement

  • Monitor changes in expression or post-translational modifications

  • Assess restoration of normal localization patterns

In Drosophila models carrying the ACO2 A252T variant, researchers observed aggravated motor deficits and dopaminergic neuron degeneration after exposure to neurotoxins such as 6-OHDA and rotenone . These findings suggest that ACO2 dysfunction may increase vulnerability to environmental stressors, providing a potential mechanism for the association between ACO2 and neurodegenerative diseases.

What is the relationship between ACO2 and cellular immunity, and how can researchers investigate this connection?

Recent research has uncovered a surprising role for ACO2 in regulating immune responses, expanding our understanding beyond its classical function in the Krebs cycle. This connection presents exciting opportunities for immunological research:

• Conserved immunomodulatory function:
  Studies in both C. elegans and mammalian cells demonstrate that ACO2 inhibits immunity against pathogenic bacteria. Genetic inhibition of ACO2:

  • Enhances pathogen resistance in C. elegans

  • Increases viability of HeLa cells upon infection with pathogenic S. aureus

  • Specifically modulates immune responses compared to inhibition of other mitochondrial enzymes

• Mechanistic pathway:
  The immunomodulatory effects of ACO2 operate through a specific metabolic-cellular signaling axis:

  • ACO2 inhibition decreases oxaloacetate levels

  • Reduced oxaloacetate triggers the mitochondrial unfolded protein response (UPRᵐᵗ)

  • UPRᵐᵗ activation upregulates transcription factor ATFS-1 (in C. elegans)

  • This cascade enhances immunity against pathogenic bacteria

• Research strategies:
  Researchers can investigate this connection using several approaches:

  • RNA interference or CRISPR-based ACO2 knockdown/knockout

  • Measurement of Krebs cycle metabolites (particularly oxaloacetate)

  • Assessment of UPRᵐᵗ activation using reporter systems

  • Transcriptome analysis to identify differentially regulated immune genes

  • Bacterial infection models to evaluate functional outcomes

• Experimental design considerations:

  • Use ACO2 antibodies to confirm knockdown efficiency

  • Monitor changes in ACO2 expression during infection

  • Compare effects to other mitochondrial protein inhibitions (e.g., COX5B, CS)

  • Assess cytokine expression profiles in ACO2-inhibited cells

This research area represents a promising therapeutic avenue, as the study authors note: "Because mitochondrial aconitase is highly conserved across phyla, a therapeutic strategy targeting ACO2 may eventually help properly control immunity in humans" .

How can researchers use ACO2 antibodies to study post-translational modifications of ACO2?

Studying post-translational modifications (PTMs) of ACO2 presents unique challenges and opportunities for understanding how this enzyme's activity is regulated under different physiological and pathological conditions. ACO2 antibodies can be powerful tools in this investigation:

• Identifying relevant modifications:
  Several PTMs have been reported to affect ACO2 function, including:

  • Oxidation of iron-sulfur clusters (affecting enzymatic activity)

  • Phosphorylation (modulating protein-protein interactions)

  • Acetylation (influencing protein stability and activity)

  • S-nitrosylation (responding to nitrosative stress)

• Experimental approaches:

  • Co-immunoprecipitation (Co-IP): Use ACO2 antibodies to pull down the protein and associated partners, followed by PTM-specific antibody detection or mass spectrometry

  • Western blotting: Combine ACO2 antibodies with PTM-specific antibodies (e.g., anti-phospho, anti-acetyl) for sequential probing

  • 2D gel electrophoresis: Separate ACO2 isoforms based on charge differences introduced by PTMs, followed by immunoblotting

  • Proximity ligation assays: Detect specific modifications in situ using ACO2 antibodies paired with PTM-specific antibodies

• Methodological considerations:

  • Include phosphatase/deacetylase inhibitors during sample preparation

  • Consider enrichment strategies for modified proteins

  • Compare modifications under different metabolic conditions

  • Validate findings using site-directed mutagenesis

  • Use mass spectrometry to identify novel modification sites

• Functional validation:

  • Correlate PTM patterns with enzymatic activity measurements

  • Examine how modifications affect protein stability and turnover

  • Assess the impact of modifications on subcellular localization

  • Investigate how PTMs influence protein-protein interactions

Understanding ACO2 post-translational modifications is particularly relevant in the context of oxidative stress and neurodegenerative diseases, where altered PTM patterns may contribute to enzyme dysfunction. Antibodies specific to modified forms of ACO2 would be valuable tools, though research in this area is still developing.

How can researchers establish reliable ACO2 knockdown models to validate antibody specificity?

Establishing reliable ACO2 knockdown models is crucial not only for validating antibody specificity but also for studying ACO2 function. Several approaches have been successfully implemented:

• RNA interference (RNAi) approaches:

  • siRNA-mediated knockdown: Successfully demonstrated in mammalian cells (e.g., HeLa cells) with significant reduction in ACO2 protein levels. This approach provides transient knockdown suitable for short-term experiments .

  • shRNA-mediated knockdown: More suitable for stable knockdown models, allowing longer-term studies of ACO2 deficiency.

  • RNAi in model organisms: Effective ACO2 (aco-2) knockdown has been demonstrated in C. elegans, providing insights into conserved functions .

• CRISPR/Cas9 genome editing:

  • More complete and stable ACO2 deficiency models

  • Allows creation of specific mutations to mimic disease-associated variants

  • Can be applied in both cell lines and animal models

• Validation protocols:

  • Western blot validation: Use ACO2 antibodies to confirm reduction in protein levels, with quantification showing at least 70-80% knockdown efficiency.

  • Functional assays: Measure aconitase enzymatic activity to confirm functional consequences.

  • Metabolic profiling: Assess changes in Krebs cycle metabolites (citrate, isocitrate, oxaloacetate, etc.) to confirm metabolic impact .

• Controls and considerations:

  • Include scrambled siRNA/shRNA controls

  • Use multiple siRNA sequences targeting different regions of ACO2 mRNA

  • Consider potential compensatory mechanisms (e.g., upregulation of related enzymes)

  • Account for off-target effects through rescue experiments

Published data demonstrates that ACO2 knockdown models show specific physiological effects, such as increased immunity against pathogenic bacteria and altered UPRᵐᵗ activation . These models provide crucial negative controls for antibody validation while simultaneously enabling functional studies of ACO2.

What are the best experimental approaches to study ACO2 in the context of oxidative stress?

Oxidative stress significantly impacts ACO2 function, as the enzyme's iron-sulfur cluster makes it particularly vulnerable to inactivation by reactive oxygen species. Researchers can employ several experimental approaches to study this relationship:

• Inducing oxidative stress:

  • Pharmacological inducers: H₂O₂, paraquat, rotenone, or 6-OHDA

  • Metabolic manipulations: Glucose deprivation, hypoxia-reoxygenation

  • Genetic approaches: Knockdown of antioxidant enzymes (SOD, catalase)

  • Environmental stressors: UV radiation, heavy metals

• Measuring ACO2 responses:

  • Protein expression: Western blot analysis using ACO2 antibodies to detect changes in total protein levels

  • Enzymatic activity: Spectrophotometric assays measuring the conversion of citrate to isocitrate

  • Protein oxidation: Oxyblot analysis to detect carbonylation of ACO2

  • Iron-sulfur cluster integrity: EPR spectroscopy or specific assays for [4Fe-4S] cluster status

• Subcellular localization studies:

  • Immunofluorescence: Using ACO2 antibodies to track potential redistribution during oxidative stress

  • Subcellular fractionation: Western blot analysis of different cellular compartments

  • Live-cell imaging: With fluorescently tagged ACO2 to monitor dynamic changes

• Linking to disease models:
  Research has shown that ACO2 deficiency increases vulnerability to Parkinson's disease, with ACO2 activity significantly decreased in PBMCs from PD patients . Experimental models can include:

  • Neurotoxin exposure (MPTP, rotenone, 6-OHDA)

  • Expression of PD-associated mutant proteins (α-synuclein, LRRK2)

  • ACO2 genetic variants found in PD patients

• Protective interventions:

  • Antioxidant treatments (NAC, vitamin E, mitochondria-targeted antioxidants)

  • Overexpression of ACO2 or ACO2 variants

  • Mitochondrial protective compounds

The experimental evidence suggests that ACO2 may serve as a potential early biomarker for assessing the effects of antioxidants in PD, and targeting energy metabolism through ACO2 could represent a therapeutic strategy for neurodegenerative disorders .

How does ACO2 interaction with other mitochondrial proteins influence its function, and how can these interactions be studied?

ACO2 functions within the complex mitochondrial environment, where interactions with other proteins can significantly impact its activity, stability, and regulation. Understanding these interactions provides insights into both normal physiology and disease states:

• Key protein interaction partners:

  • Krebs cycle enzymes: Physical and functional interactions with citrate synthase, isocitrate dehydrogenase, and other components

  • Mitochondrial chaperones: Interactions with mtHSP70 and other chaperones that assist in proper folding

  • Mitochondrial quality control machinery: Potential interactions with PINK1, Parkin, and other proteins involved in mitophagy

  • UPRᵐᵗ components: Connections to ATFS-1 (in C. elegans) and similar factors in mammals

• Methodological approaches:

  • Co-immunoprecipitation (Co-IP): Using ACO2 antibodies to pull down protein complexes

  • Proximity-based labeling: BioID or APEX2 approaches to identify proteins in close proximity to ACO2

  • Yeast two-hybrid screening: To identify novel interaction partners

  • Förster resonance energy transfer (FRET): To detect protein-protein interactions in living cells

  • Cross-linking mass spectrometry: To capture transient interactions

• Functional consequences to investigate:

  • Effects on ACO2 enzymatic activity

  • Influence on protein stability and turnover

  • Alteration of subcellular localization

  • Changes in PTM patterns

  • Metabolic adaptations and consequences

• Disease-relevant interactions:
  Research has revealed connections between ACO2 and cellular pathways relevant to neurodegenerative diseases:

  • Autophagy machinery (LC3, Atg5)

  • Epigenetic regulators influencing histone acetylation (H3K9, H4K5)

  • Mitochondrial stress response pathways

• Experimental design considerations:

  • Use specific antibodies for both ACO2 and potential interacting partners

  • Include appropriate controls (e.g., IgG control for Co-IP)

  • Validate interactions using multiple complementary techniques

  • Consider both endogenous proteins and tagged versions

  • Evaluate interactions under different physiological conditions

Understanding these protein interactions may reveal novel regulatory mechanisms and potential therapeutic targets. For example, the connection between ACO2 and autophagy-related genes suggests complex regulatory networks beyond its canonical metabolic role .

What are the critical quality control measures for validating ACO2 antibody performance?

Rigorous validation of ACO2 antibodies is essential for generating reliable and reproducible research data. Comprehensive quality control should include:

• Specificity validation:

  • Western blot analysis: Confirm single band at expected molecular weight (85 kDa)

  • Knockout/knockdown controls: Compare signal between normal and ACO2-depleted samples

  • Peptide competition assays: Pre-incubation with immunizing peptide should abolish specific signal

  • Cross-reactivity testing: Evaluate potential cross-reactivity with related proteins (e.g., ACO1)

• Sensitivity assessment:

  • Dilution series: Determine lower detection limits using serial dilutions of samples

  • Low-expressing samples: Test detection in tissues/cells with minimal ACO2 expression

  • Signal-to-noise ratio: Evaluate background relative to specific signal

• Reproducibility testing:

  • Lot-to-lot consistency: Compare results from different antibody lots

  • Inter-laboratory validation: Collaborate to verify consistent performance across laboratories

  • Protocol robustness: Test performance across variation in experimental conditions

• Application-specific validation:

  • For WB: Optimize loading amounts, blocking conditions, and detection methods

  • For IHC/IF: Validate fixation and antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • For Flow cytometry: Optimize permeabilization and staining conditions

  • For IP: Confirm efficient pull-down of the target protein

• Positive control samples:
  Several tissues have been validated as reliable positive controls for ACO2 antibodies:

  • Brain tissue (human, mouse, rat, pig, rabbit)

  • Heart tissue (mouse, rat)

  • Liver tissue (human)

  • Cell lines: HeLa, HEK-293, PC-12, Neuro-2a

Researchers should document all validation steps and include appropriate controls in each experiment. This comprehensive approach ensures that observed results genuinely reflect ACO2 biology rather than technical artifacts.

How can researchers effectively compare and integrate data from different ACO2 antibody sources?

• Systematic antibody comparison:

  • Epitope mapping: Determine which region of ACO2 each antibody recognizes

  • Side-by-side testing: Compare performance using identical samples and protocols

  • Signal intensity calibration: Develop methods to normalize signal intensity differences

  • Specificity profiling: Characterize potential cross-reactivity patterns

• Data normalization strategies:

  • Internal reference standards: Include common samples across experiments

  • Standardized positive controls: Use well-characterized cell lines or tissues

  • Ratiometric approaches: Express results relative to housekeeping proteins

  • Absolute quantification: Consider using purified ACO2 protein standards

• Metadata documentation:
  Document critical parameters for each experiment:

  • Antibody source, catalog number, and lot

  • Detailed experimental protocols

  • Image acquisition settings

  • Data analysis methods

• Statistical approaches:

  • Meta-analysis methods: Combine data from multiple studies

  • Correction factors: Apply when systematic differences are identified

  • Outlier identification: Establish criteria for excluding problematic data points

  • Confidence intervals: Report uncertainty associated with measurements

• Practical integration example:
  When comparing ACO2 expression data between studies using different antibodies:

  • Focus on relative changes rather than absolute values

  • Validate key findings using multiple antibodies

  • Consider the specific applications each antibody is validated for

  • Account for differences in species reactivity (e.g., some antibodies show broader reactivity patterns than others)

What are the most reliable quantification methods for ACO2 expression analysis?

Accurate quantification of ACO2 expression is critical for meaningful data interpretation. Researchers should consider several methodological approaches based on their specific research questions:

• Western blot quantification:

  • Densitometry analysis: Measure band intensity relative to loading controls

  • Normalization strategies: Use total protein staining (e.g., Ponceau S) in addition to housekeeping proteins

  • Dynamic range considerations: Ensure signal falls within the linear range of detection

  • Software tools: Use specialized analysis software with background subtraction capabilities

• Immunohistochemistry quantification:

  • Scoring systems: Develop structured systems based on staining intensity and distribution

  • Digital image analysis: Use software to quantify DAB staining intensity

  • Whole slide scanning: Analyze entire tissue sections to account for heterogeneity

  • Multiplex approaches: Co-stain with cell-type markers for cell-specific quantification

• Immunofluorescence quantification:

  • Mean fluorescence intensity: Measure within regions of interest

  • Object-based approaches: Count and measure discrete mitochondrial structures

  • Colocalization analysis: Quantify overlap with mitochondrial markers

  • 3D reconstruction: Account for the full volume in confocal z-stacks

• Flow cytometry:

  • Median fluorescence intensity: More robust to outliers than mean

  • Population gating: Isolate specific cell populations before measuring ACO2

  • Controls: Include fluorescence minus one (FMO) controls

  • Standardization: Use calibration beads to normalize between experiments

• Complementary techniques:

  • qRT-PCR: Quantify ACO2 mRNA levels as a complement to protein data

  • Enzymatic activity assays: Measure functional ACO2 activity

  • Mass spectrometry: Consider for absolute quantification of ACO2 protein

• Technical considerations:

  • Sample size determination: Perform power calculations to ensure adequate statistical power

  • Biological replicates: Include samples from multiple individuals/experiments

  • Technical replicates: Perform multiple measurements of each sample

  • Blinding: Analyze samples without knowledge of experimental conditions

Studies examining ACO2 in disease contexts have used multiple complementary approaches. For example, research on PD patients evaluated both ACO2 protein levels and enzymatic activity in PBMCs, revealing that while protein expression was increased, enzymatic activity was significantly decreased . This highlights the importance of integrating multiple quantification approaches for a complete understanding of ACO2 biology.